Merck KGaA takes its I/O option on F-star Therapeutics; Nephron spends $215M, eyeing spot in Covid-19 vaccine chain
→Merck KGaA has taken an early option on an immuno-oncology program developed at F-star Therapeutics. This is their second option in the collaboration. And they added a pair of preclinical discovery programs to the alliance as well.
→ Any biotech going public these days wouldn’t feel right if they didn’t upsize the offering. And that’s just what Phase I biotech Pandion Therapeutics did. The autoimmune company is now selling 7 million shares, a 1.5 million share bump, for $16 to $18 a share.
→ Eyeing a spot in the Covid-19 vaccine supply chain, generic drugmakers Nephron Pharmaceuticals is spending $215 million to add a new office, warehousing and vaccine production space — along with 380 jobs — in Lexington County, South Carolina. Nephron CEO Lou Kennedy told FiercePharma that they are in talks with two large pharmas to use the vaccine space, scheduled to be completed in early 2021, for Covid-19 vaccine production.
→ Cell coding biotech Berkeley Lights raised its IPO range from $16-$18 to $19-$20, and now plans to raise $144 million as the California company tries to cash in on a record-breaking 2020 IPO boom.